` PHAR (Pharming Group NV) vs S&P 500 Comparison - Alpha Spread

PHAR
vs
S&P 500

Over the past 12 months, PHAR has outperformed S&P 500, delivering a return of 26% compared to the S&P 500's 10% growth.

Stocks Performance
PHAR vs S&P 500

Loading
PHAR
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
PHAR vs S&P 500

Loading
PHAR
S&P 500
Difference
www.alphaspread.com

Performance By Year
PHAR vs S&P 500

Loading
PHAR
S&P 500
Add Stock

Competitors Performance
Pharming Group NV vs Peers

S&P 500
PHAR
ABBV
AMGN
GILD
VRTX
Add Stock

Pharming Group NV
Glance View

Market Cap
701.3m USD
Industry
Biotechnology

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

PHAR Intrinsic Value
12.83 USD
Undervaluation 19%
Intrinsic Value
Price
Back to Top